WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs™ - NSCLC in Combination with Nivolumab (Opdivo ) for the Treatment of Non-Small Cell Lung Cancer

Press/Media

PeriodMay 28 2020

Media coverage

1

Media coverage

  • TitleWindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs™ - NSCLC in Combination with Nivolumab (Opdivo ) for the Treatment of Non-Small Cell Lung Cancer
    Media name/outletGlobal English (Middle East and North Africa Financial Network)
    Country/TerritoryJordan
    Date05/28/20
    PersonsMartin Edelman